Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00086957 · ClinicalTrials.gov registry record · Phase 1

Gefitinib, Trastuzumab, and Docetaxel in Treating Patients With Metastatic Breast Cancer

A Phase 1 study of Breast Cancer, sponsored by City of Hope Medical Center.

Completed
Registry status
Phase 1
Development phase
31
Enrollment target
6
Study locations

NCT00086957 is a Phase 1 study of Breast Cancer that has completed, run by City of Hope Medical Center. The registered enrollment target is 31 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (99% lower). The trial reports 6 study locations across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00086957, a Phase 1 study of Breast Cancer, has completed, sponsored by City of Hope Medical Center.

COMPLETED
Registry status
Phase 1
Development phase
31 participants
Enrollment target
6
Study locations

Study Summary

RATIONALE: Gefitinib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. Monoclonal antibodies such as trastuzumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Drugs used in chemotherapy, such as docetaxel, work in different ways to stop tumor cells from dividing so they stop growing or die. Combining gefitinib and trastuzumab with docetaxel may kill more tumor cells. PURPOSE: This phase I/II trial is studying the best dose of docetaxel when given together with gefitinib and trastuzumab in treating patients with metastatic breast cancer.

Conditions Studied

Breast Cancer

Interventions

  • DRUG docetaxel
  • BIOLOGICAL trastuzumab
  • DRUG gefitinib

Study Locations (6)

California

  • Tower Cancer Research Foundation - Beverly Hills
  • City of Hope Comprehensive Cancer Center - Duarte
  • Hematology Oncology Consultants-Hemet - Hemet
  • Breastlink Medical Group, Incorporated at Long Beach Memorial Medical Center - Long Beach
  • USC/Norris Comprehensive Cancer Center and Hospital - Los Angeles
  • City of Hope Medical Group - Pasadena

Trial Details

FieldValue
Enrollment Target 31 participants
Start Date 2004-01
Est. Completion 2015-08
Phase Phase 1

Sponsor

City of Hope Medical Center

582 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00086957

The ClinicalTrials.gov registry entry for NCT00086957 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (99% lower). The listed sponsor is City of Hope Medical Center, which has 582 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 3 interventions - of which docetaxel is the first listed.

NCT00086957 reports 6 study locations spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT00086957 about?

NCT00086957 is a clinical study titled "Gefitinib, Trastuzumab, and Docetaxel in Treating Patients With Metastatic Breast Cancer". RATIONALE: Gefitinib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. Monoclonal antibodies such as trastuzumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Drugs used in chemotherapy, such...

What is the current status of trial NCT00086957?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 31 participants. The study started on 2004-01. Estimated completion is 2015-08.

What conditions does trial NCT00086957 study?

This clinical trial studies the following conditions: Breast Cancer.

What interventions are being tested in trial NCT00086957?

The interventions under investigation include: docetaxel (DRUG), trastuzumab (BIOLOGICAL), gefitinib (DRUG).

Who is sponsoring clinical trial NCT00086957?

This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00086957 being conducted?

This trial has 6 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Breast Cancer

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.